Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The risk of myocardial infarction (MI) in patients with diabetes is greater than for patients without diabetes. Consequently, prophylactic treatment is recommended for patients with diabetes and risk factors for ischemic heart disease. We aimed to estimate the risk of adverse cardiac events in patients with and without diabetes with and without coronary artery disease (CAD) after coronary angiography (CAG). RESEARCH DESIGN AND METHODS: A population-based cohort of patients registered in the Western Denmark Heart Registry who underwent CAG between 1 January 2003 and 31 December 2012 was stratified according to the presence or absence of obstructive CAD and diabetes. End points were death, cardiac death, and MI. Unadjusted and adjusted rate ratios (RRs) were calculated by using patients without diabetes and without CAD as the reference group. RESULTS: We included 93,866 patients of whom 12,544 (13.4%) had diabetes at the time of CAG. Median follow-up was 4.1 years. Patients with and without diabetes without obstructive CAD had the same adjusted risk of death (RR 1.03 [95% CI 0.92–1.15]), cardiac death (RR 1.21 [95% CI 0.90–1.64]), and MI (RR 0.88 [95% CI 0.65–1.17]). Patients with diabetes without CAD were more often treated with statins (75.3% vs. 46.0%) and aspirin (65.7% vs. 52.7%) than patients without diabetes and CAD. CONCLUSIONS: In a real-world population, patients with diabetes with high rates of statin and aspirin treatment had the same risk of cardiovascular events as patients without diabetes in the absence of angiographically significant CAD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A gain-of-function mutation in apoC3 that leads to high ApoC-III levels can also cause severe HTG by inhibiting the activity of LPL”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [380]
In the citing paper
“whereas loss-of-function mutations are associated with a favourable lipid profile with low TG levels [380].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [380]
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742 · cited 1×
“Comorbidity The Charlson comorbidity index score was estimated for each patient on the CAG date (17).”
MethodDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · cited 1×
“Statin treatment has similarly been associated with a significant reduction of coronary events in patients with diabetes (29,30).”
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Recent data indicate that DM per se increases CVD risk about two-fold on average, but the risk is subject to wide variation depending on the population and current aggressive prophylactic therapy.(401,404) Importantly, those with DM and CAD are at substantially higher CVD risk for future events.”
Diabetes Mellitus–Related All‐Cause and Cardiovascular Mortality in a National Cohort of Adults
Raghavan, S., Vassy, J. L., Ho, Y., Song, R. J., Gagnon, D. R., Cho, K., Wilson, P. W. F., & Phillips, L. S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011295 · Cited by 563
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 186
The Western Denmark Heart Registry
Schmidt, M., Mæng, M., Madsen, M., Sørensen, H. T., Jensen, L. O., & Jakobsen, C.-J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.110 · Cited by 148
Self-citationBanach, M., Surma, S., Reiner, Z., Katsiki, N., Penson, P. E., Fras, Z., Sahebkar, A., Paneni, F., Rizzo, M., & Kastelein, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01684-5 · Cited by 100
“[9] Moreover, at the DMT2 diagnosis, other CV risk factors typically coexist, such as abdominal obesity, dyslipidemia, arterial hypertension, and metabolic sydnrome [10, 11].”
BackgroundGiugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012356 · Cited by 99
Diabetic heart disease: A clinical update
Rajbhandari, J., Fernandez, C. J., Agarwal, M., Yeap, B. X. Y., & Pappachan, J. M. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.383 · Cited by 102
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 97
Olesen, K. K. W., Madsen, M., Gyldenkerne, C., Thrane, P. G., Würtz, M., Thim, T., Jensen, L. O., Eikelboom, J. W., Bøtker, H. E., Sørensen, H. T., et al. (2019) · Stroke · doi:10.1161/strokeaha.119.026099 · Cited by 61
“Based on our earlier reports that DM patients without CAD did not have an increased risk of MI, our hypotheses was that absence of CAD would remove the DM-related risk of ischemic stroke.(5,6) However, our main finding contrasts this hypothesis.”
BackgroundResultSelf-citationClass effect for SGLT-2 inhibitors: a tale of 9 drugs
Giugliano, D., & Esposito, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0899-9 · Cited by 49
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
“Cardiovascular events Overall, CVD affects approximately about 32% of all persons with T2D [25] in whom CV risk is mitigated primarily with statins and aspirin [26].”
BackgroundOlesen, K. K. W., Gyldenkerne, C., Thim, T., Thomsen, R. W., & Maeng, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001803 · Cited by 28
Self-citationLøgstrup, B. B., Olesen, K. K. W., Mašić, D., Gyldenkerne, C., Thrane, P. G., Ellingsen, T., Bøtker, H. E., & Mæng, M. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217154 · Cited by 38
Self-citationBanach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Diabetes and coronary artery disease as risk factors for dementia
Olesen, K. K. W., Thrane, P. G., Gyldenkerne, C., Thomsen, R. W., Mortensen, J. K., Kristensen, S. D., & Mæng, M. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae153 · Cited by 33
Self-citationGyldenkerne, C., Mæng, M., Kjøller‐Hansen, L., Maehara, A., Zhou, Z., Ben‐Yehuda, O., Bøtker, H. E., Engstrøm, T., Matsumura, M., Mintz, G. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061983 · Cited by 25
Self-citationMæng, M., Steg, P. G., Bhatt, D. L., Hohnloser, S. H., Nordaby, M., Miede, C., Kimura, T., Lip, G. Y. H., Oldgren, J., ten Berg, J. M., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.07.059 · Cited by 24
Giugliano, D., Ceriello, A., De Nicola, L., Perrone‐Filardi, P., Cosentino, F., & Esposito, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13881 · Cited by 22
“Within this context, it has been shown that Danish T2D patients without angiographically significant CHD have the same risk of future cardiovascular events as patients without diabetes, if treated with appropriate doses of statin and aspirin.(10)”
BackgroundGyldenkerne, C., Olesen, K. K. W., Madsen, M., Thim, T., Jensen, L. O., Raungaard, B., Sørensen, H. T., Bøtker, H. E., & Mæng, M. (2019) · Clinical Epidemiology · doi:10.2147/clep.s200173 · Cited by 21
“Assessment of CAD by CAG has been described as a valid prognostic tool in risk stratification of diabetes patients.(4) In the current study, we conducted a median follow-up of 3 years in diabetes patients undergoing CAG to evaluate whether increasing extent of obstructive CAD is associated with incremental MI and deat…”
MethodResultSelf-citationde la Cruz, S., Gutierrez-Mariscal, F. M., Alcala-Diaz, J. F., Quintana‐Navarro, G. M., Podadera-Herreros, A., Cardelo, M. P., Torres-Peña, J. D., Larriva, A. P. A.-D., Pérez‐Martínez, P., Delgado‐Lista, J., et al. (2021) · Nutrients · doi:10.3390/nu13041217 · Cited by 21
“Importantly, when both conditions are simultaneously present, the risk and severity of future cardiovascular events is considerably increased [2], and it can be further aggravated with the presence of metabolic risk factors such as hypertension, dyslipidaemia, or obesity [3].”
BackgroundOlesen, K. K. W., Riis, A. H., Nielsen, L. H., Steffensen, F. H., Nørgaard, B. L., Jensen, J. M., Poulsen, P. L., Thim, T., Bøtker, H. E., Sørensen, H. T., et al. (2019) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jez010 · Cited by 20
Self-citationThe Western Denmark Heart Registry and Population-Based National Health Registries
Gyldenkerne, C., Olesen, K. K. W., Thrane, P. G., Hansen, M. K., Stødkilde-Jørgensen, N., Andersen, M. H., Mortensen, M. B., Jensen, J. M., Nørgaard, B. L., Sørensen, H. T., et al. (2024) · Clinical Epidemiology · doi:10.2147/clep.s488498 · Cited by 18
Self-citationType 2 diabetes and cardiovascular prevention: the dogmas disputed
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2017) · Endocrine · doi:10.1007/s12020-017-1418-y · Cited by 17
Gyldenkerne, C., Olesen, K. K. W., Thrane, P. G., Madsen, M., Thim, T., Würtz, M., Jensen, L. O., Raungaard, B., Poulsen, P. L., Bøtker, H. E., et al. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120941809 · Cited by 14
Self-citationRen, J., Zhang, H., Shao, X., Gu, T., Hu, S., Zhang, Y., Jiang, C. Q., Zhang, J., Wu, X., Liu, X., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133352 · Cited by 14
Collier, A., Connelly, P. J., Hair, M. D., Cameron, L., Ghosh, S. K., & Waugh, N. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13334 · Cited by 12
Gyldenkerne, C., Olesen, K. K. W., Madsen, M., Thim, T., Jensen, L. O., Raungaard, B., Sørensen, H. T., Bøtker, H. E., & Mæng, M. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119836227 · Cited by 12
Self-citation15-Year Cardiovascular Risk in Patients With Angina Without Obstructive Coronary Arteries
Olesen, K. K. W., Madsen, M., Würtz, M., Thim, T., Mortensen, M. B., Sørensen, H. T., & Mæng, M. (2025) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2025.09.014 · Cited by 11
Self-citationFras, Z., Sahebkar, A., & Banach, M. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00424-y · Cited by 11
Olesen, K. K. W., Madsen, M., Gyldenkerne, C., Thrane, P. G., Thim, T., Jensen, L. O., Bøtker, H. E., Sørensen, H. T., & Mæng, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01212-x · Cited by 10
Self-citationSakanaka, A., Katakami, N., Furuno, M., Nishizawa, H., Omori, K., Taya, N., Ishikawa, A., Mayumi, S., Inoue, M., Isomura, E. T., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1074285 · Cited by 9
“Furthermore, diabetes itself is an independent risk factor for CVD, and recent findings indicate that its presence increases that risk by approximately two-fold on average, though there are wide variations depending on the subject population and prophylactic treatment received (Sattar, 2013; Olesen et al., 2017).”
BackgroundSchrör, K., Kristensen, S. D., Storey, R. F., & Verheugt, F. W. A. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1694774 · Cited by 9
Jin, J., Cao, Y., Wu, L., You, X.-D., Guo, N., Guo, Y., Wu, N., Zhu, C., Xu, R., Liu, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-037340 · Cited by 8
Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
Guardiola, M., Rehues, P., Amigó, N., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Girona, J., Martínez‐Montoro, J. I., Ortega, E., Pérez, A., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14214 · Cited by 8
“42 Atherogenic dyslipidaemia, 43 which presents as a cluster of plasma lipid and lipoprotein abnormalities that are meta-bolically interrelated and triggered by an increase in large VLDL particles associated with atherogenic remnants, small dense LDL and small TG-rich dense HDL particles, is…”
Finck, T., Will, A., Hendrich, E., Martinoff, S. A., & Hadamitzky, M. (2019) · Heart and Vessels · doi:10.1007/s00380-018-01339-0 · Cited by 8
Olesen, K. K. W., Heide‐Jørgensen, U., Thim, T., Thomsen, R. W., Bøtker, H. E., Sørensen, H. T., & Mæng, M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab040 · Cited by 7
Self-citationTibaut, M., Mankoč, S., & Petrovič, D. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00845-3 · Cited by 6
Diabetes is a cardiovascular disease, isn’t it?
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.006 · Cited by 6
Tonnesen, P. T., Olesen, K. K. W., Thrane, P. G., Gyldenkerne, C., Peters, C. D., Buus, N. H., & Mæng, M. (2023) · Clinical Epidemiology · doi:10.2147/clep.s433983 · Cited by 4
Self-citationBirindwa, G., Mæng, M., Thrane, P. G., Gyldenkerne, C., Thomsen, R. W., & Olesen, K. K. W. (2024) · Clinical Epidemiology · doi:10.2147/clep.s463363 · Cited by 4
Self-citationLa importancia del control de la dislipemia en el paciente con diabetes mellitus tipo 2
Carrasco-Sánchez, F. J. (2021) · doi:10.52102/control_dislipemia/art-1 · Cited by 4
Ali, U., Ashraf, A., & Ahmad, A. (2022) · Pakistan Heart Journal · doi:10.47144/phj.v55i1.2158 · Cited by 3
“According to some epidemiological studies, diabetic patients have four folds increased risk of CVD mortality.(9)”
BackgroundResultInfluentialPrognostic implications of quantified coronary atherosclerosis and myocardial perfusion in diabetes
Mäenpää, M., Jukema, R., van Diemen, P. A., Bär, S., Raijmakers, P. G. H. M., Sprengers, R. W., Driessen, R. S., Bax, J. J., Knaapen, P., Knuuti, J. M., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03006-x · Cited by 1
“…with diabetes had 1.3–1.6-fold crude rates for MI, cardiac death, and all-cause death as compared with non-diabetic patients in the absence of angiographically obstructive coronary artery stenosis, but adjustment by additional variables rendered most of these differences non-significant [7].”
InfluentialGökçek, İ., Sönmez, B. M., Yücel, Ç., Gökçek, M. B., & Ayyıldız, F. A. (2022) · Eskisehir Medical Journal Eskisehir City Hospital · doi:10.48176/esmj.2022.51 · Cited by 1
Coronary Angiography Evaluation of Atherosclerosis in Diabetic Patients
Hasanović, A., Šapčanin, A., & Hasanović, J. (2019) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-030-17971-7_49
Mæng, M., Bhatt, D. L., Nordaby, M., Miede, C., & Cannon, C. P. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.01.207
Løgstrup, B. B., Olesen, K. K. W., Mašić, D., Gyldenkerne, C., Thrane, P. G., Ellingsen, T., Bøtker, H. E., & Mæng, M. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219231
Self-citationCollier, A., Hair, M. D., Cameron, L., Ghosh, S., Boyle, J. G., Walters, M., & Waugh, N. (2021) · Journal of Epidemiology and Public Health Reviews · doi:10.16966/2471-8211.209
“In addition, hypertension may be better managed among type 2 patients with greater use of cardio-protective antihypertensive medications such as angiotensin converting enzyme inhibitors or angiotensin receptor blockers [25].”
BackgroundGopal, S. N., Yallanki, H. P., Priya, K. L., & Kannan, R. (2024) · Romanian Medical Journal · doi:10.37897/rmj.2024.3.11
Olesen, K. K. W., Madsen, M., Gyldenkerne, C., Thrane, P. G., Thim, T., Jensen, L. O., Bøtker, H. E., Sørensen, H. T., & Mæng, M. (2021) · Figshare · doi:10.6084/m9.figshare.13627003
Self-citationTibaut, M., Mankoč, S., & Petrovič, D. (2020) · Figshare · doi:10.6084/m9.figshare.13363998
Raisi, A. (2024) · Institutional Research Information System University of Ferrara (University of Ferrara)
Correlation Between Erectile Dysfunction and Coronary Heart Disease in Men at RSUP. Prof. Ngoerah
Wangsadinata, S. C., Pramesemara, I. G. N., Antara, I. M. P. S., & Wardana, I. N. G. (2025) · Indonesian Andrology and Biomedical Journal · doi:10.20473/iabj.v6i1.65603
Haybar, H., Memar, M., Seyedian, S. M., Azizidoost, S., & Mohammadi, S. (2026) · Health Science Reports · doi:10.1002/hsr2.71872
Epidemiology of Cardiovascular disease and associated risk factors in Gaza Strip- Palestine
Jamee, A. (2019) · theses.fr (ABES) · doi:10.70675/f3c10b16z6420z46b0z81b5z75ec59d4399e
Diabetes, coronary artery disease, and clinical outcomes: Insights from multimodality imaging
Mäenpää, M. (2026) · UTUPub (University of Turku)
مستويات داء السكري في الدم وعلاقته بأمراض السكت ة الدماغية: دراسة فسيولوجية بمنطقة الخمس – ليبيا
الصغير, م. ح., العريفي, إ. ع., & الجحاوي, ع. ح. ع. (2025) · مجلة شمال إفريقيا للنشر العلمي (NAJSP)
Metadata
- Authors
- Olesen, K. K. W., Madsen, M., Egholm, G., Thim, T., Jensen, L. O., Raungaard, B., Bøtker, H. E., Sørensen, H. T., & Maeng, M.
- Affiliations
- Aarhus University Hospital (DK)
- Odense University Hospital (DK)
- Aalborg University Hospital (DK)
- Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-06-08
- Volume
- 40
- Issue
- 8
- Pages
- 1103-1110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2621500879
- Cited by
- 51
- References
- 32
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 11 · 2020: 7 · 2019: 15 · 2018: 2 · 2017: 2
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Funders
- Hjerteforeningen (14-R97-A5144-22860)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes mellitus, myocardial infarction, coronary artery disease, coronary angiography, statins, aspirin, secondary prevention, cardiovascular risk, cardiovascular mortality, ischemic heart disease, Western Denmark Heart Registry
- MeSH terms
- Aged, Aspirin, Coronary Artery Disease, Denmark, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Registries, Risk Factors, Cohort Studies, Comorbidity, Coronary Angiography, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.